The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study
- PMID: 28554015
- PMCID: PMC5523851
- DOI: 10.1016/j.atherosclerosis.2017.05.014
The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study
Abstract
Background and aims: Lipoprotein(a) [Lp(a)] is a proatherogenic lipoprotein associated with coronary heart disease, ischemic stroke, and more recently aortic stenosis and heart failure (HF). We examined the association of Lp(a) levels with incident HF hospitalization in the Atherosclerosis Risk in Communities (ARIC) study. We also assessed the relationship between Lp(a) levels and arterial stiffness as a potential mechanism for development of HF.
Methods: Lp(a) was measured in 14,154 ARIC participants without prevalent HF at ARIC visit 1 (1987-1989). The association of Lp(a) quintiles with incident HF hospitalization was assessed using Cox proportional-hazards models. Arterial stiffness parameters were stratified based on Lp(a) quintiles, and p-trend was calculated across ordered groups.
Results: At a median follow-up of 23.4 years, there were 2605 incident HF hospitalizations. Lp(a) levels were directly associated with incident HF hospitalization in models adjusted for age, race, gender, systolic blood pressure, history of hypertension, diabetes, smoking status, body mass index, heart rate, and high-density lipoprotein cholesterol (quintile 5 vs. quintile 1: hazard ratio [HR] 1.24, 95% confidence interval [CI] 1.09-1.41; p-trend across increasing quintiles <0.01), but not after excluding prevalent and incident myocardial infarction cases (HR 1.07, 95% CI 0.91-1.27; p-trend = 0.70). When adjusted for age, gender, and race, Lp(a) quintiles were not significantly associated with arterial stiffness parameters.
Conclusions: Increased Lp(a) levels were associated with increased risk of incident HF hospitalization. After excluding prevalent and incident myocardial infarction, the association was no longer significant. Lp(a) levels were not associated with arterial stiffness parameters.
Keywords: Heart failure; Lipoproteins; Risk factors; Risk prediction.
Copyright © 2017 Elsevier B.V. All rights reserved.
Conflict of interest statement
A. Agarwala: none
Y. Pokharel: supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number T32HL110837.
A. Saeed: none
W. Sun: none
S. S. Virani: none
V. Nambi: provisional patent along with Roche, Baylor College of Medicine, University of North Carolina on use of biomarkers in prediction of heart failure, regional advisory board Sanofi Regeneron, event adjudicator for a study sponsored by Siemens, site PI for study sponsored by Merck
C. Ndumele: none,
E. Shahar: none
G. Heiss: none
E. Boerwinkle: officer, director, trustee, or other fiduciary role for Codified Genomics
S. Konety: none
R. C. Hoogeveen: research grants from Denka Seiken, Ltd., and Roche.
C. M. Ballantyne: consultant fees/honoraria from Abbott Diagnostic, Amarin, Amgen, AstraZeneca, Eli Lilly, Esperion, Genzyme, Ionis, Matinas BioPharma Inc, Merck & Company, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo; research/research grants from Abbott Diagnostic, Amarin, Amgen, Eli Lilly, Esperion, Novartis, Otsuka, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo, Takeda; a provisional patent (patent #61721475) entitled ”Biomarkers to Improve Prediction of Heart Failure Risk” was filed by Drs. Ballantyne, Hoogeveen, and Nambi, Baylor College of Medicine and Roche.
Figures

Similar articles
-
Lp(a) [Lipoprotein(a)]-Related Risk of Heart Failure Is Evident in Whites but Not in Other Racial/Ethnic Groups.Arterioscler Thromb Vasc Biol. 2018 Oct;38(10):2498-2504. doi: 10.1161/ATVBAHA.118.311220. Arterioscler Thromb Vasc Biol. 2018. PMID: 30354212 Free PMC article.
-
Serum parathyroid hormone and 25-hydroxyvitamin D concentrations and risk of incident heart failure: the Multi-Ethnic Study of Atherosclerosis.J Am Heart Assoc. 2014 Dec 2;3(6):e001278. doi: 10.1161/JAHA.114.001278. J Am Heart Assoc. 2014. PMID: 25468653 Free PMC article.
-
Kansas City Cardiomyopathy Questionnaire Score Is Associated With Incident Heart Failure Hospitalization in Patients With Chronic Kidney Disease Without Previously Diagnosed Heart Failure: Chronic Renal Insufficiency Cohort Study.Circ Heart Fail. 2015 Jul;8(4):702-8. doi: 10.1161/CIRCHEARTFAILURE.115.002097. Epub 2015 May 18. Circ Heart Fail. 2015. PMID: 25985796 Free PMC article.
-
Risk for Incident Heart Failure: A Subject-Level Meta-Analysis From the Heart "OMics" in AGEing (HOMAGE) Study.J Am Heart Assoc. 2017 May 2;6(5):e005231. doi: 10.1161/JAHA.116.005231. J Am Heart Assoc. 2017. PMID: 28465299 Free PMC article. Review.
-
Resting heart rate and risk of incident heart failure: three prospective cohort studies and a systematic meta-analysis.J Am Heart Assoc. 2015 Jan 14;4(1):e001364. doi: 10.1161/JAHA.114.001364. J Am Heart Assoc. 2015. PMID: 25589535 Free PMC article. Review.
Cited by
-
Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives.Int J Environ Res Public Health. 2023 Sep 6;20(18):6721. doi: 10.3390/ijerph20186721. Int J Environ Res Public Health. 2023. PMID: 37754581 Free PMC article. Review.
-
Current Management and Future Perspectives in the Treatment of Lp(a) with a Focus on the Prevention of Cardiovascular Diseases.Pharmaceuticals (Basel). 2023 Jun 23;16(7):919. doi: 10.3390/ph16070919. Pharmaceuticals (Basel). 2023. PMID: 37513831 Free PMC article. Review.
-
Blood biomarkers of progressive atherosclerosis and restenosis after stenting of symptomatic intracranial artery stenosis.Sci Rep. 2021 Aug 2;11(1):15599. doi: 10.1038/s41598-021-95135-y. Sci Rep. 2021. PMID: 34341413 Free PMC article.
-
Association of lipoprotein (a) and 1 year prognosis in patients with heart failure with reduced ejection fraction.ESC Heart Fail. 2022 Aug;9(4):2399-2406. doi: 10.1002/ehf2.13933. Epub 2022 Apr 13. ESC Heart Fail. 2022. PMID: 35419980 Free PMC article.
-
Lipoprotein(a) and Heart Failure Among Black and White Participants in Atherosclerosis Risk in Communities Study, Framingham Offspring Study, and Multi-Ethnic Study of Atherosclerosis: The Pooling Project.J Am Heart Assoc. 2025 Jun 3;14(11):e038608. doi: 10.1161/JAHA.124.038608. Epub 2025 May 26. J Am Heart Assoc. 2025. PMID: 40417812 Free PMC article.
References
-
- Virani SS, Brautbar A, Davis BC, Nambi V, Hoogeveen RC, Sharrett AR, Coresh J, Mosley TH, Morrisett JD, Catellier DJ, Folsom AR, Boerwinkle E, Ballantyne CM. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2012;125:241–249. - PMC - PubMed
-
- Bennet A, Di Angelantonio E, Erqou S, Eiriksdottir G, Sigurdsson G, Woodward M, Rumley A, Lowe GD, Danesh J, Gudnason V. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med. 2008;168:598–608. - PubMed
-
- Johannsen TH, Kamstrup PR, Andersen RV, Jensen GB, Sillesen H, Tybjaerg-Hansen A, Nordestgaard BG. Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease. J Clin Endocrinol Metab. 2009;94:1264–1273. - PubMed
-
- Suk Danik J, Rifai N, Buring JE, Ridker PM. Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA. 2006;296:1363–1370. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- HHSN268201100012C/HL/NHLBI NIH HHS/United States
- HHSN268201100009I/HL/NHLBI NIH HHS/United States
- HHSN268201100010C/HL/NHLBI NIH HHS/United States
- HHSN268201100008C/HL/NHLBI NIH HHS/United States
- HHSN268201100005G/HL/NHLBI NIH HHS/United States
- HHSN268201100008I/HL/NHLBI NIH HHS/United States
- HHSN268201100007C/HL/NHLBI NIH HHS/United States
- HHSN268201100011I/HL/NHLBI NIH HHS/United States
- HHSN268201100011C/HL/NHLBI NIH HHS/United States
- HHSN268201100006C/HL/NHLBI NIH HHS/United States
- HHSN268201100005I/HL/NHLBI NIH HHS/United States
- T32 HL110837/HL/NHLBI NIH HHS/United States
- HHSN268201100009C/HL/NHLBI NIH HHS/United States
- HHSN268201100005C/HL/NHLBI NIH HHS/United States
- HHSN268201100007I/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous